Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 9/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16107326 | 1.00 | P2RY12 (0.48) | P2RY12ADORA3AHCY | |
| SCHEMBL1828941 | 1.00 | P2RY12 (0.48) | P2RY12ADORA3AHCY | |
| SCHEMBL1838603 | 0.94 | P2RY12 (0.49) | P2RY12ADORA3AHCY | |
| SCHEMBL29688154 | 0.94 | P2RY12 (0.49) | P2RY12ADORA3AHCY | |
| SCHEMBL1835723 | 0.89 | P2RY12 (0.48) | P2RY12ADORA3 | |
| SCHEMBL29687768 | 0.89 | P2RY12 (0.48) | P2RY12ADORA3 | |
| SCHEMBL6619320 | 0.87 | P2RY12 (0.39) | P2RY12ADORA3 | |
| SCHEMBL1831150 | 0.83 | P2RY12 (0.49) | P2RY12ADORA3 | |
| SCHEMBL14890553 | 0.83 | P2RY12 (0.49) | P2RY12ADORA3 | |
| SCHEMBL17679487 | 0.83 | P2RY12 (0.43) | P2RY12ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220270454-A1 | TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ELEVATED AVP | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-08-25 | — | — | US | disclosed |
| US-11354990-B2 | Treatment of kidney diseases associated with elevated AVP | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11354990-B2 | Treatment of kidney diseases associated with elevated AVP | AVPR2, PKD1, AVPR1A | P2RY12 321/4885ADORA3 85/4885AHCY 271/4885 |
| US-20220270454-A1 | TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ELEVATED AVP | AVPR2, PKD1, AVPR1A | P2RY12 334/4885ADORA3 81/4885AHCY 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.